Bremelanotide Acetate (PT-141; PT141; PT 141; Vyleesi), the acetatea salt of Bremelanotide, is a peptide analogue of alpha-MSH peptide acting as a melanocortin receptor agonist.

Bremelanotide (PT-141; PT141; PT 141; Vyleesi), a peptide analogue of alpha-MSH peptide acting as a melanocortin receptor agonist approved in 2019 for the treatment of hypoactive sexual desire disorder in premenopausal women.

Setmelanotide (BIM-22493; RM-493; IRC-022493; Imcivree) is a novel, selective and peptidyl agonist of melanocortin 4 receptor (MC4R) that has been approved in 2020 for use as an anti-obesity medication for the treatment of genetic obesity.

Afamelanotide (Melanotan I; MT-I; CUV-1647; MBJ05; trade name Scenesse) is a synthetic peptide analog of α-melanocyte stimulating hormone (α-MSH), acting as a melanocortin receptor agonist and has been approved for use to prevent skin damage from the sun in people with erythropoietic protoporphyria in EU and USA.

JNJ-10229570 is a novel, potent and selective antagonist of melanocortin receptor 1 (MC1R) and melanocortin receptor 5 (MC5R) with the potential to treat primary human sebaceous cells and for the treatment of acne and other sebaceous gland pathologies.